Related Experiment Video
Updated: May 28, 2026
08:54
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
Mast cell driven immunometabolism as a therapeutic entry point in ESCC
Zhifeng Qu1, Xuewei Zheng2,3, Anshun Zhao4
1Department of Radiation Oncology, Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, China.
Frontiers in Cell and Developmental Biology
|May 27, 2026
Summary
Mast cells (MCs) in esophageal squamous cell carcinoma (ESCC) promote tumor growth and immune suppression by altering metabolism. Targeting MCs and their mediators offers new therapeutic strategies for this aggressive cancer.
Area of Science:
- Oncology
- Immunology
- Metabolic Research
Background:
- Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with limited treatment efficacy.
- Tumor metabolic reprogramming and immune dysfunction are interconnected but poorly understood in ESCC.
- Mast cells (MCs) are increasingly recognized for their role in tumor microenvironments.
Purpose of the Study:
- To investigate the role of mast cells (MCs) in shaping the metabolic and immune landscape of esophageal squamous cell carcinoma (ESCC).
- To explore the mechanisms by which MC-derived mediators influence tumor cell metabolism and immune evasion.
- To identify potential therapeutic targets within MC-mediated pathways for ESCC treatment.
Main Methods:
- Analysis of MC spatial distribution within tumor microenvironments (stromal, vascular, hypoxic zones).
- Investigation of MC-derived lipid mediators (prostaglandins, leukotrienes, PAF) and their effects on tumor cell metabolism.
- Assessment of MC impact on immune cell function (dendritic cells, cytotoxic T cells) and extracellular matrix remodeling.
- Application of single cell and spatial transcriptomic analyses to characterize MC heterogeneity in ESCC.
Main Results:
- MCs are spatially associated with metabolic stress zones in ESCC.
- MC-derived lipid mediators amplify tumor cell metabolic programs and create an immunosuppressive environment.
- MCs impair dendritic cell priming and cytotoxic T cell function.
- MCs contribute to extracellular matrix remodeling, facilitating tumor invasion.
- Significant heterogeneity exists among tumor-infiltrating MCs, with distinct subsets influencing tumor progression.
Conclusions:
- MCs play a critical role in coordinating metabolic reprogramming and immune dysfunction in ESCC.
- Targeting MC-linked mediators or lipid metabolic enzymes presents promising therapeutic avenues.
- Understanding MC heterogeneity is key for developing effective combination therapies for ESCC.
- Further research into MC mechanisms may enable biomarker-guided patient stratification and novel treatment strategies.
Related Concept Videos
01:19Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...